Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

To investigate the effects of semaglutide on fasting and postprandial glucose and lipid responses, and on gastric emptying.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

After each 12-week treatment period, glucose and lipid metabolism were assessed before and after standardized meals.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Some participants received a placebo instead of Semaglutide, giving a reference point.

Each person switched between Semaglutide and the comparison at some point, usually with a gap in between.

This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.

Gastric emptying (paracetamol absorption test) and peptide YY (PYY) response were also assessed.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Gastric Emptying, Glucagon-Like Peptides, Hypoglycemic Agents and Lipid Metabolism.

The authors tagged it with the keywords GLP-1 analogue, glucose metabolism, incretin therapy, insulin analogues, obesity therapy and phase I-II study.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page.